Turner Heather D
Insider CIK 1403571 · SGMO SVP and General Counsel · OREX VP, Gen. Counsel & Secretary · AVLN Director · ATRA VP, General Counsel & Sec. · LBRX Chief Executive Officer, Director · LYEL Chief General Counsel · TERN Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| TERN Terns Pharmaceuticals, Inc | D To issuer deriv | 2026-05-05 | 2026-05-05 | 1,697 | — | $0 | 0 | SEC↗ |
| TERN Terns Pharmaceuticals, Inc | D To issuer deriv | 2026-05-05 | 2026-05-05 | 64,000 | — | $0 | 0 | SEC↗ |
| TERN Terns Pharmaceuticals, Inc | D To issuer deriv | 2026-05-05 | 2026-05-05 | 45,000 | — | $0 | 0 | SEC↗ |
| AVLN Avalyn Pharma Inc. | A Award deriv | 2026-04-29 | 2026-05-01 | 26,978 | — | $0 | 26,978 | SEC↗ |
| TERN Terns Pharmaceuticals, Inc | A Award deriv | 2026-02-01 | 2026-02-02 | 1,697 | — | $0 | 1,697 | SEC↗ |
| LBRX LB PHARMACEUTICALS INC | D To issuer deriv | 2025-09-10 | 2025-09-12 | 175,706 | — | $0 | 0 | SEC↗ |
| LBRX LB PHARMACEUTICALS INC | D To issuer deriv | 2025-09-10 | 2025-09-12 | 7,857 | — | $0 | 0 | SEC↗ |
| LBRX LB PHARMACEUTICALS INC | A Award deriv | 2025-09-10 | 2025-09-12 | 971,828 | — | $0 | 971,828 | SEC↗ |
| LBRX LB PHARMACEUTICALS INC | A Award deriv | 2025-09-10 | 2025-09-12 | 7,857 | — | $0 | 7,857 | SEC↗ |
| LBRX LB PHARMACEUTICALS INC | A Award deriv | 2025-09-10 | 2025-09-12 | 175,706 | — | $0 | 175,706 | SEC↗ |
| TERN Terns Pharmaceuticals, Inc | A Award deriv | 2025-06-11 | 2025-06-12 | 45,000 | — | $0 | 45,000 | SEC↗ |
| TERN Terns Pharmaceuticals, Inc | A Award deriv | 2024-11-18 | 2024-11-19 | 64,000 | — | $0 | 64,000 | SEC↗ |
| LYEL Lyell Immunopharma, Inc. | A Award deriv | 2022-03-16 | 2022-03-18 | 300,000 | — | $0 | 300,000 | SEC↗ |
| SGMO SANGAMO THERAPEUTICS, INC | A Award deriv | 2019-02-25 | 2019-02-27 | 115,500 | — | $0 | 115,500 | SEC↗ |
| SGMO SANGAMO THERAPEUTICS, INC | A Award | 2019-02-25 | 2019-02-27 | 19,250 | — | $0 | 19,250 | SEC↗ |
| SGMO SANGAMO THERAPEUTICS, INC | A Award deriv | 2018-02-28 | 2018-03-02 | 200,000 | — | $0 | 200,000 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | S Sale | 2018-02-09 | 2018-02-12 | 4,123 | $37.38 | $154.1K | 72,989 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | S Sale | 2018-02-09 | 2018-02-12 | 4,596 | $36.63 | $168.4K | 77,112 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | S Sale | 2018-02-09 | 2018-02-12 | 1,562 | $41.69 | $65.1K | 69,494 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | S Sale | 2018-02-09 | 2018-02-12 | 600 | $40.62 | $24.4K | 71,056 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | S Sale | 2018-02-09 | 2018-02-12 | 733 | $39.66 | $29.1K | 71,656 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | S Sale | 2018-02-09 | 2018-02-12 | 600 | $38.63 | $23.2K | 72,389 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | F Tax w/h | 2018-02-06 | 2018-02-08 | 4,434 | $35.80 | $158.7K | 81,708 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | S Sale | 2017-02-09 | 2017-02-10 | 11,582 | $15.70 | $181.8K | 86,775 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | S Sale | 2017-02-09 | 2017-02-10 | 633 | $16.16 | $10.2K | 86,142 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | A Award | 2017-02-06 | 2017-02-08 | 49,500 | — | $0 | 98,357 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | A Award deriv | 2016-09-22 | 2016-09-23 | 40,000 | — | $0 | 40,000 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | A Award | 2016-02-09 | 2016-02-11 | 48,857 | — | $0 | 48,857 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | A Award deriv | 2015-12-17 | 2015-12-21 | 65,000 | — | $0 | 65,000 | SEC↗ |
| ATRA Atara Biotherapeutics, Inc | A Award deriv | 2015-08-03 | 2016-03-04 | 130,000 | — | $0 | 130,000 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | A Award deriv | 2015-02-03 | 2015-02-05 | 153,050 | — | $0 | 153,050 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | M Exercise deriv | 2014-12-02 | 2014-12-04 | 22,643 | — | $0 | 656,932 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | M Exercise | 2014-12-02 | 2014-12-04 | 22,643 | $1.66 | $37.6K | 22,643 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | S Sale | 2014-12-02 | 2014-12-04 | 22,643 | $6.00 | $135.9K | 0 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | M Exercise deriv | 2014-11-25 | 2014-11-26 | 7,382 | — | $0 | 679,575 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | S Sale | 2014-11-25 | 2014-11-26 | 7,382 | $6.00 | $44.3K | 0 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | M Exercise | 2014-11-25 | 2014-11-26 | 7,382 | $1.66 | $12.3K | 7,382 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | M Exercise deriv | 2014-11-24 | 2014-11-26 | 24,006 | — | $0 | 686,957 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | M Exercise | 2014-11-24 | 2014-11-26 | 24,006 | $1.66 | $39.8K | 24,006 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | S Sale | 2014-11-24 | 2014-11-26 | 24,006 | $5.77 | $138.5K | 0 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | M Exercise deriv | 2014-09-22 | 2014-09-22 | 300,000 | — | $0 | 710,963 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | S Sale | 2014-09-22 | 2014-09-22 | 300,000 | $4.47 | $1.34M | 0 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | M Exercise | 2014-09-22 | 2014-09-22 | 300,000 | $1.66 | $498.0K | 300,000 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | A Award deriv | 2014-02-07 | 2014-02-11 | 205,000 | — | $0 | 205,000 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | A Award | 2013-11-29 | 2014-02-11 | 3,980 | $5.34 | $21.3K | 3,980 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | A Award deriv | 2013-02-15 | 2013-02-19 | 240,000 | — | $0 | 240,000 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | M Exercise deriv | 2012-07-17 | 2012-07-19 | 82,433 | — | $0 | 1,010,963 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | S Sale | 2012-07-17 | 2012-07-19 | 82,433 | $7.68 | $633.1K | 0 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | M Exercise | 2012-07-17 | 2012-07-19 | 82,433 | $1.66 | $136.8K | 82,433 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | A Award deriv | 2012-01-25 | 2012-01-26 | 350,000 | — | $0 | 350,000 | SEC↗ |